2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…2017 American Transplant Congress
Clinical Outcomes of ABO and HLA Incompatible Kidney Transplantation – Nationwide Cohort Study.
Background This is a nationwide cohort study to investigate the impact of anti-A/B antibody or donor specific anti-HLA antibody (HLA-DSA) on the clinical outcomes in…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…2017 American Transplant Congress
Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.
Purpose: To determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to a negative flow cytometry crossmatch (FCXM) despite desensitization. Methods:…2017 American Transplant Congress
Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…2017 American Transplant Congress
Does HLA Class of Complement Activating Donor Specific Antibodies Matter: Single Centre Retrospective Analysis of Renal Allograft Outcomes.
Introduction. Complement activating donor specific antibodies may be associated with worse outcomes in a cohort of patients who have undergone HLA-AIT. We looked for differences…2017 American Transplant Congress
Impact of Serum EDTA Treatment on Identification of Unacceptable Antigens for Kidney Transplant Candidates.
Pathology, University of Chicago Medicine, Chicago, IL
BACKGROUND AND AIMS: The prozone effect is one factor causing false negative reactions in HLA antibody testing. EDTA, which is commonly used to remove this…2016 American Transplant Congress
Anti-IL6R Therapy (Tocilizumab) Improves Long-Term Patient & Graft Survival in Patients with Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction:Extending the functionality of renal allografts is an essential goal of transplant medicine. HS patients (pts) are at increased risk for chronic ABMR (CABMR) due…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 15
- Next Page »